Extract

The purpose of this study is to assess the efficacy and safety of MK-1029, compared with placebo, in subjects aged 18 to 75 years with evidence of asthma uncontrolled on montelukast, using measures of lung function (forced expiratory volume in 1 second [FEV1], peak expiratory flow [PEF]) and subject-reported endpoints, including symptoms, short-acting β-agonist (SABA) use, and percentage of days with asthma exacerbations. The primary objective is to demonstrate that MK-1029, compared with placebo, results in improvement in FEV1 after 4 weeks of treatment with MK-1029.

Inclusion criteria

• Adult subjects, 18 to 75 years of age, with persistent asthma

Links

• euctr
• ictrp